Alpha Teknova, Inc. (TKNO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $2.74. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Valuation: TKNO trades at a trailing Price-to-Earnings (P/E) of -8.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.85.
Financials: revenue is $41M, -0.4%/yr average growth. Net income is $17M (loss), growing at +28.4%/yr. Net profit margin is -42.6% (negative). Gross margin is 33.2% (-9 pp trend).
Balance sheet: total debt is $15M against $69M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 4.58 (strong liquidity). Debt-to-assets is 14.6%. Total assets: $104M.
Analyst outlook: 2 / 3 analysts rate TKNO as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 21/100 (Fail), Future 55/100 (Partial), Income 10/100 (Fail).
